The designer cytokine hyper-IL-6 mediates growth inhibition and GM-CSF-dependent rejection of B16 melanoma cells. - Wikidata - awgldk - TriplyDB

The designer cytokine hyper-IL-6 mediates growth inhibition and GM-CSF-dependent rejection of B16 melanoma cells.

The designer cytokine hyper-IL-6 mediates growth inhibition and GM-CSF-dependent rejection of B16 melanoma cells.

http://www.wikidata.org/entity/Q40810927

about

Interleukin-6 trans-signalling differentially regulates proliferation, migration, adhesion and maspin expression in human prostate cancer cells Engineered monoclonal antibody with novel antigen-sweeping activity in vivo.Cytokines and chemokines are expressed at different levels in small and large murine colon-26 tumors following intratumoral injections of CpG ODN.IL-6 trans-signaling licenses mouse and human tumor microvascular gateways for trafficking of cytotoxic T cells.IBC's 22nd Annual Antibody Engineering and 9th Annual Antibody Therapeutics International Conferences and the 2011 Annual Meeting of The Antibody Society, December 5-8, 2011, San Diego, CA.Hyper-interleukin-11 novel designer molecular adjuvant targeting gp130 for whole cell cancer vaccines.Gene-modified tumor vaccine secreting a designer cytokine Hyper-Interleukin-6 is an effective therapy in mice bearing orthotopic renal cell cancer.Loss of oncostatin M receptor beta in metastatic melanoma cells.Unraveling viral interleukin-6 binding to gp130 and activation of STAT-signaling pathways independently of the interleukin-6 receptor.Whole cell melanoma vaccine genetically modified to stem cells like phenotype generates specific immune responses to ALDH1A1 and long-term survival in advanced melanoma patients

P2860

Q33690450-6E3D8245-538E-48E1-B58A-83803CD3AD33 Q34718085-29DD3DC9-CBFF-420A-94EC-EF02714E53E3 Q34928326-F22D546C-288A-4B23-B7F6-B0FD2BB27F85 Q35369944-E56BCE81-E59E-49A2-BC09-4A76B846F2E3 Q35992493-4C6C01FD-45CF-4EB8-9C5A-13C61DD8679A Q37945276-3A978F60-59F1-44F0-91DC-5E247EF6598F Q39737606-7AC89188-3329-428B-A7D9-A240D075F6F4 Q40243654-3123172D-0B43-49A3-A52D-80B26E062624 Q41839982-93DB426B-7925-4D6A-85A1-53F763985FD2 Q58129598-55630F35-61E0-412C-B4C0-34FDBC86E6E8

P2860

The designer cytokine hyper-IL-6 mediates growth inhibition and GM-CSF-dependent rejection of B16 melanoma cells.

http://www.wikidata.org/entity/Q40810927

description

2001 nî lūn-bûn

@nan

2001年の論文

@ja

2001年論文

@yue

2001年論文

@zh-hant

2001年論文

@zh-hk

2001年論文

@zh-mo

2001年論文

@zh-tw

2001年论文

@wuu

2001年论文

@zh

2001年论文

@zh-cn

name

The designer cytokine hyper-IL ...... jection of B16 melanoma cells.

@en

type

label

The designer cytokine hyper-IL ...... jection of B16 melanoma cells.

@en

prefLabel

The designer cytokine hyper-IL ...... jection of B16 melanoma cells.

@en

P1433

Q40810927-1332A872-EF7F-4498-B9BF-57F76020F167

P1476

Q40810927-0332A137-F90B-4637-8F8A-1A5F0ABBBA69

P2093

Q40810927-164E876C-C9C6-481B-9C57-54D2C1E4BCF0

Q40810927-1C3A47C6-F1A9-49E2-893F-8D0CC356C4B5

Q40810927-3C949909-06F3-4F13-B4D3-6A5E965D5AFA

Q40810927-69416E91-8606-4CD1-92DD-149CBAFED187

Q40810927-83CA438C-A79E-463C-9613-DADA3FB49040

Q40810927-98066261-937C-40C3-850B-D6AF3CEF4BFA

Q40810927-B29AB8B2-6A01-47AC-8F22-033A27A7050C

Q40810927-E48494CE-070C-4327-98FC-FD0B38EDE2E9

P2860

Q40810927-054D8579-2CDA-4CC5-9F95-1B198833F431

Q40810927-1B064FBD-7A1E-4A88-BC97-03CED0B2CBC9

Q40810927-2FC61530-69BE-4248-8F40-31831C5BBB8D

Q40810927-3A6B3C5F-0362-4353-8DD5-BE2D5B898EFE

Q40810927-3AF2FC95-4258-4EE7-AE9A-8CF048331B1A

Q40810927-4193AA77-1CFA-4819-A265-DB9615C98A87

Q40810927-5CBE5F07-A533-4A90-9A86-E79A1E4AF245

Q40810927-651D85A7-094F-4586-80C0-5A30665E699D

Q40810927-73C77332-0144-43BD-B2E9-6774C47E8EB1

Q40810927-786DB317-0813-405D-800A-A0B8315C573F

P2888

Q40810927-CE8553F1-F8A9-4CC9-A78B-20725FA14B41

P304

Q40810927-4216E269-E566-4AFA-97F7-CCD816D0AD18

P31

Q40810927-F00C1C5E-882E-4367-A453-EA0F31D02896

P356

Q40810927-5B757708-5188-43AE-991A-1D8C9C000071

P407

Q40810927-9CBA1A3C-A0E3-4AB1-9C37-8CD611ACCF90

P433

Q40810927-3864B83C-0D1A-4DB4-BE00-9FC57D2E7D4A

P478

Q40810927-B07977EF-F108-4AF9-842D-5AEC080B6318

P50

Q40810927-63AC604A-267E-4977-B7CA-BC1179416791

P577

Q40810927-CE5F8D41-3EEE-41D8-96F7-44B09CCF462C

P5875

Q40810927-370E6021-445B-4A9C-8832-5247EA5CB5A0

P6179

Q40810927-12692424-009F-4693-B723-6695BBB5ABA9

P698

Q40810927-7EBF59BA-E2EF-4715-9FB7-BA4AEB811D5D

P356

P1433

P1476

The designer cytokine hyper-IL ...... jection of B16 melanoma cells.

@en

P2093

Blessing M

http://www.w3.org/2001/XMLSchema#string

Fischer M

http://www.w3.org/2001/XMLSchema#string

Mackiewicz A

http://www.w3.org/2001/XMLSchema#string

Mann A

http://www.w3.org/2001/XMLSchema#string

Ozbek S

http://www.w3.org/2001/XMLSchema#string

Peters M

http://www.w3.org/2001/XMLSchema#string

Rose-John S

http://www.w3.org/2001/XMLSchema#string

Schirmacher P

http://www.w3.org/2001/XMLSchema#string

P2860

Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 beta receptor components

Dysregulated interleukin 6 expression produces a syndrome resembling Castleman's disease in mice.

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.

Association of transcription factor APRF and protein kinase Jak1 with the interleukin-6 signal transducer gp130.

Tumor suppression after tumor cell-targeted tumor necrosis factor alpha gene transfer

Overexpression of bone morphogenetic protein-6 (BMP-6) in the epidermis of transgenic mice: inhibition or stimulation of proliferation depending on the pattern of transgene expression and formation of psoriatic lesions.

Antitumor activity of recombinant interleukin 6 in mice

Interleukin 6 induces human immunodeficiency virus expression in infected monocytic cells alone and in synergy with tumor necrosis factor alpha by transcriptional and post-transcriptional mechanisms.

The function of the soluble interleukin 6 (IL-6) receptor in vivo: sensitization of human soluble IL-6 receptor transgenic mice towards IL-6 and prolongation of the plasma half-life of IL-6.

Interleukin-6 and the acute phase response.

P2888

P304

972-979

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.ONC.1204180

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P50

P577

2001-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

12020844

http://www.w3.org/2001/XMLSchema#string

P6179

1002187112

http://www.w3.org/2001/XMLSchema#string

P698

11314032

http://www.w3.org/2001/XMLSchema#string